|
1
|
Islami F, Miller KD, Siegel RL, Fedewa SA,
Ward EM and Jemal A: Disparities in liver cancer occurrence in the
United States by race/ethnicity and state. CA Cancer J Clin.
67:273–289. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Herold C, Reck T, Fischler P, Ott R,
Radespiel-Troeger M, Ganslmayer M, Hohenberger W, Hahn EG and
Schuppan D: Prognosis of a large cohort of patients with
hepatocellular carcinoma in a single European centre. Liver.
22:23–28. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xiong H, Ni Z, He J, Jiang S, Li X, He J,
Gong W, Zheng L, Chen S, Li B, et al: LncRNA HULC triggers
autophagy via stabilizing Sirt1 and attenuates the chemosensitivity
of HCC cells. Oncogene. 36:3528–3540. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang H, Feng Z, Huang R, Xia Z, Xiang G
and Zhang J: MicroRNA-449 suppresses proliferation of hepatoma cell
lines through blockade lipid metabolic pathway related to SIRT1.
Int J Oncol. 45:2143–2152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bhalla KN: Epigenetic and chromatin
modifiers as targeted therapy of hematologic malignancies. J Clin
Oncol. 23:3971–3993. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bertoli G, Cava C and Castiglioni I:
MicroRNAs: New biomarkers for diagnosis, prognosis, therapy
prediction and therapeutic tools for breast cancer. Theranostics.
5:1122–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brennecke J, Hipfner DR, Stark A, Russell
RB and Cohen SM: Bantam encodes a developmentally regulated
microRNA that controls cell proliferation and regulates the
proapoptotic gene hid in drosophila. Cell. 113:25–36. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hatfield SD, Shcherbata HR, Fischer KA,
Nakahara K, Carthew RW and Ruohola-Baker H: Stem cell division is
regulated by the microRNA pathway. Nature. 435:974–978. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pekarsky Y, Santanam U, Cimmino A,
Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG,
Rassenti L, et al: Tcl1 expression in chronic lymphocytic leukemia
is regulated by miR-29 and miR-181. Cancer Res. 66:11590–11593.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fang F, Chang RM, Yu L, Lei X, Xiao S,
Yang H and Yang LY: MicroRNA-188-5p suppresses tumor cell
proliferation and metastasis by directly targeting FGF5 in
hepatocellular carcinoma. J Hepatol. 63:874–885. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Firestein R, Blander G, Michan S,
Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S,
de Cabo R, Fuchs C, et al: The SIRT1 deacetylase suppresses
intestinal tumorigenesis and colon cancer growth. PLoS One.
3:e20202008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guarente L: Calorie restriction and
sirtuins revisited. Genes Dev. 27:2072–2085. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen J, Zhang B, Wong N, Lo AW, To KF,
Chan AW, Ng MH, Ho CY, Cheng SH, Lai PB, et al: Sirtuin 1 is
upregulated in a subset of hepatocellular carcinomas where it is
essential for telomere maintenance and tumor cell growth. Cancer
Res. 71:4138–4149. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Portmann S, Fahrner R, Lechleiter A, Keogh
A, Overney S, Laemmle A, Mikami K, Montani M, Tschan MP, Candinas D
and Stroka D: Antitumor effect of SIRT1 inhibition in human HCC
tumor models in vitro and in vivo. Mol Cancer Ther. 12:499–508.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong CW, Wang YX, Du FT, Ding W and Hu SY:
Low miR-29c expression is a prognostic marker in hepatocellular
carcinoma. Genet Mol Res. 15:2016. View Article : Google Scholar
|
|
17
|
Lu Y, Hu J, Sun W, Li S, Deng S and Li M:
MiR-29c inhibits cell growth, invasion, and migration of pancreatic
cancer by targeting ITGB1. Onco Targets Ther. 9:99–109.
2015.PubMed/NCBI
|
|
18
|
Zhao X, Li J, Huang S, Wan X, Luo H and Wu
D: MiRNA-29c regulates cell growth and invasion by targeting CDK6
in bladder cancer. Am J Transl Res. 7:1382–1389. 2015.PubMed/NCBI
|
|
19
|
Wang B, Li D, Sidler C, Rodriguez-Juarez
R, Singh N, Heyns M, Ilnytskyy Y, Bronson RT and Kovalchuk O: A
suppressive role of ionizing radiation-responsive miR-29c in the
development of liver carcinoma via targeting WIP1. Oncotarget.
6:9937–9950. 2015.PubMed/NCBI
|
|
20
|
Yu B, Chen X, Li J, Gu Q, Zhu Z, Li C, Su
L and Liu B: microRNA-29c inhibits cell proliferation by targeting
NASP in human gastric cancer. BMC Cancer. 17:1092017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lopez-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo P, He T, Jiang R and Li G:
MicroRNA-423-5p targets O-GlcNAc transferase to induce apoptosis in
cardiomyocytes. Mol Med Rep. 12:1163–1168. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng L, Yang Q, Li C, Dai L, Yang Y, Wang
Q, Ding Y, Zhang J, Liu L, Zhang S, et al: DDA1, a novel oncogene,
promotes lung cancer progression through regulation of cell cycle.
J Cell Mol Med. 21:1532–1544. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dai L, Cui X, Zhang X, Cheng L, Liu Y,
Yang Y, Fan P, Wang Q, Lin Y, Zhang J, et al: SARI inhibits
angiogenesis and tumour growth of human colon cancer through
directly targeting ceruloplasmin. Nat Commun. 7:119962016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang Y, Liu C, Yang J, Liu G, Feng F,
Tang J, Hu L, Li L, Jiang F, Chen C, et al: MiR-20a triggers
metastasis of gallbladder carcinoma. J Hepatol. 59:518–527. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang X, Zhang XF, Lu X, Jia HL, Liang L,
Dong QZ, Ye QH and Qin LX: MicroRNA-26a suppresses angiogenesis in
human hepatocellular carcinoma by targeting hepatocyte growth
factor-cMet pathway. Hepatology. 59:1874–1885. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Altman DG, McShane LM, Sauerbrei W and
Taube SE: Reporting recommendations for tumor marker prognostic
studies (REMARK): Explanation and elaboration. PLoS Med.
9:e10012162012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cummins JM, He Y, Leary RJ, Pagliarini R,
Diaz LA Jr, Sjoblom T, Barad O, Bentwich Z, Szafranska AE,
Labourier E, et al: The colorectal microRNAome. Proc Natl Acad Sci
USA. 103:3687–3692. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fabbri M, Garzon R, Cimmino A, Liu Z,
Zanesi N, Callegari E, Liu S, Alder H, Costinean S,
Fernandez-Cymering C, et al: MicroRNA-29 family reverts aberrant
methylation in lung cancer by targeting DNA methyltransferases 3A
and 3B. Proc Natl Acad Sci USA. 104:15805–15810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Porkka KP, Pfeiffer MJ, Waltering KK,
Vessella RL, Tammela TL and Visakorpi T: MicroRNA expression
profiling in prostate cancer. Cancer Res. 67:6130–6135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pang L, Gu W, Wang N, Hu J, Cui X, Zhang
J, Zhao J, Liu C, Zhang W, Zou H, et al: MicroRNA-29c-5p suppresses
gallbladder carcinoma progression by directly targeting CPEB4 and
inhibiting the MAPK pathway. Clin Exp Pharmacol Physiol.
24:445–457. 2017.(In Chinese).
|
|
34
|
Brennecke J, Stark A, Russell RB and Cohen
SM: Principles of microRNA-target recognition. PLoS Biol.
3:e852005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu L, Bi N, Wu L, Ding X, Men Y, Zhou W,
Li L, Zhang W, Shi S, Song Y and Wang L: MicroRNA-29c functions as
a tumor suppressor by targeting VEGFA in lung adenocarcinoma. Mol
Cancer. 16:502017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen HC, Jeng YM, Yuan RH, Hsu HC and Chen
YL: SIRT1 promotes tumorigenesis and resistance to chemotherapy in
hepatocellular carcinoma and its expression predicts poor
prognosis. Ann Surg Oncol. 19:2011–2019. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu Y, Meng X, Huang C and Li J: Emerging
role of silent information regulator 1 (SIRT1) in hepatocellular
carcinoma: A potential therapeutic target. Tumour Biol.
36:4063–4074. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Choi HN, Bae JS, Jamiyandorj U, Noh SJ,
Park HS, Jang KY, Chung MJ, Kang MJ, Lee DG and Moon WS: Expression
and role of SIRT1 in hepatocellular carcinoma. Oncol Rep.
26:503–510. 2011.PubMed/NCBI
|
|
39
|
Shuang T, Wang M, Zhou Y and Shi C:
Over-expression of Sirt1 contributes to chemoresistance and
indicates poor prognosis in serous epithelial ovarian cancer (EOC).
Med Oncol. 32:2602015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ziebarth AJ, Nowsheen S, Steg AD, Shah MM,
Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M,
et al: Endoglin (CD105) contributes to platinum resistance and is a
target for tumor-specific therapy in epithelial ovarian cancer.
Clin Cancer Res. 19:170–182. 2013. View Article : Google Scholar : PubMed/NCBI
|
